Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics. TransMedics Group's (NASDAQ:TMDX) investors will be pleased with their massive 349% return over the last five years The Stock ...
Sarepta Inks Global Licensing Deal With Arrowhead, Announces $500 Mln Share Buyback Program
In exchange, Arrowhead will receive an upfront payment of $500 million and an equity investment of $325 million in its common stock. The company will also receive $250 million in annual installments of $50 million over five years, along with milestone payments and royalties.
Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...
Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback